Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)
Combination treatment of molecular targeted and external radiotherapy is a promising strategy and was shown to improve local tumor control in a HNSCC xenograft model. To enhance the therapeutic value of this approach, this study investigated the underlying molecular response. Subcutaneous HNSCC FaDu...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/25dba7d79733444bab324fa7b79bf155 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:25dba7d79733444bab324fa7b79bf155 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:25dba7d79733444bab324fa7b79bf1552021-11-25T17:01:01ZMolecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)10.3390/cancers132255952072-6694https://doaj.org/article/25dba7d79733444bab324fa7b79bf1552021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5595https://doaj.org/toc/2072-6694Combination treatment of molecular targeted and external radiotherapy is a promising strategy and was shown to improve local tumor control in a HNSCC xenograft model. To enhance the therapeutic value of this approach, this study investigated the underlying molecular response. Subcutaneous HNSCC FaDu<sub>DD</sub> xenografts were treated with single or combination therapy (X-ray: 0, 2, 4 Gy; anti-EGFR antibody (Cetuximab) (un-)labeled with Yttrium-90 (<sup>90</sup>Y)). Tumors were excised 24 h post respective treatment. Residual DNA double strand breaks (DSB), mRNA expression of DNA damage response related genes, immunoblotting, tumor histology, and immunohistological staining were analyzed. An increase in number and complexity of residual DNA DSB was observed in FaDu<sub>DD</sub> tumors exposed to the combination treatment of external irradiation and <sup>90</sup>Y-Cetuximab relative to controls. The increase was observed in a low oxygenated area, suggesting the expansion of DNA DSB damages. Upregulation of genes encoding p21<sup>cip1/waf1</sup> (<i>CDKN1A</i>) and GADD45α (<i>GADD45A</i>) was determined in the combination treatment group, and immunoblotting as well as immunohistochemistry confirmed the upregulation of p21<sup>cip1/waf1</sup>. The increase in residual γH2AX foci leads to the blockage of cell cycle transition and subsequently to cell death, which could be observed in the upregulation of p21<sup>cip1/waf1</sup> expression and an elevated number of cleaved caspase-3 positive cells. Overall, a complex interplay between DNA damage repair and programmed cell death accounts for the potential benefit of the combination therapy using <sup>90</sup>Y-Cetuximab and external radiotherapy.Treewut RassamegevanonLouis FeindtLydia KoiJohannes MüllerRobert FreudenbergSteffen LöckWiebke SihverEnes ÇevikAriane Christel KühnCläre von NeubeckAnnett LingeHans-Jürgen PietzschJörg KotzerkeMichael BaumannMechthild KrauseAntje DietrichMDPI AGarticlemolecular targeted radiotherapyDNA damage responseCetuximabcell death inductionexternal beam radiotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5595, p 5595 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
molecular targeted radiotherapy DNA damage response Cetuximab cell death induction external beam radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
molecular targeted radiotherapy DNA damage response Cetuximab cell death induction external beam radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Treewut Rassamegevanon Louis Feindt Lydia Koi Johannes Müller Robert Freudenberg Steffen Löck Wiebke Sihver Enes Çevik Ariane Christel Kühn Cläre von Neubeck Annett Linge Hans-Jürgen Pietzsch Jörg Kotzerke Michael Baumann Mechthild Krause Antje Dietrich Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| description |
Combination treatment of molecular targeted and external radiotherapy is a promising strategy and was shown to improve local tumor control in a HNSCC xenograft model. To enhance the therapeutic value of this approach, this study investigated the underlying molecular response. Subcutaneous HNSCC FaDu<sub>DD</sub> xenografts were treated with single or combination therapy (X-ray: 0, 2, 4 Gy; anti-EGFR antibody (Cetuximab) (un-)labeled with Yttrium-90 (<sup>90</sup>Y)). Tumors were excised 24 h post respective treatment. Residual DNA double strand breaks (DSB), mRNA expression of DNA damage response related genes, immunoblotting, tumor histology, and immunohistological staining were analyzed. An increase in number and complexity of residual DNA DSB was observed in FaDu<sub>DD</sub> tumors exposed to the combination treatment of external irradiation and <sup>90</sup>Y-Cetuximab relative to controls. The increase was observed in a low oxygenated area, suggesting the expansion of DNA DSB damages. Upregulation of genes encoding p21<sup>cip1/waf1</sup> (<i>CDKN1A</i>) and GADD45α (<i>GADD45A</i>) was determined in the combination treatment group, and immunoblotting as well as immunohistochemistry confirmed the upregulation of p21<sup>cip1/waf1</sup>. The increase in residual γH2AX foci leads to the blockage of cell cycle transition and subsequently to cell death, which could be observed in the upregulation of p21<sup>cip1/waf1</sup> expression and an elevated number of cleaved caspase-3 positive cells. Overall, a complex interplay between DNA damage repair and programmed cell death accounts for the potential benefit of the combination therapy using <sup>90</sup>Y-Cetuximab and external radiotherapy. |
| format |
article |
| author |
Treewut Rassamegevanon Louis Feindt Lydia Koi Johannes Müller Robert Freudenberg Steffen Löck Wiebke Sihver Enes Çevik Ariane Christel Kühn Cläre von Neubeck Annett Linge Hans-Jürgen Pietzsch Jörg Kotzerke Michael Baumann Mechthild Krause Antje Dietrich |
| author_facet |
Treewut Rassamegevanon Louis Feindt Lydia Koi Johannes Müller Robert Freudenberg Steffen Löck Wiebke Sihver Enes Çevik Ariane Christel Kühn Cläre von Neubeck Annett Linge Hans-Jürgen Pietzsch Jörg Kotzerke Michael Baumann Mechthild Krause Antje Dietrich |
| author_sort |
Treewut Rassamegevanon |
| title |
Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_short |
Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_full |
Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_fullStr |
Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_full_unstemmed |
Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_sort |
molecular response to combined molecular- and external radiotherapy in head and neck squamous cell carcinoma (hnscc) |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/25dba7d79733444bab324fa7b79bf155 |
| work_keys_str_mv |
AT treewutrassamegevanon molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT louisfeindt molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT lydiakoi molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT johannesmuller molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT robertfreudenberg molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT steffenlock molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT wiebkesihver molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT enescevik molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT arianechristelkuhn molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT clarevonneubeck molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT annettlinge molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT hansjurgenpietzsch molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT jorgkotzerke molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT michaelbaumann molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT mechthildkrause molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc AT antjedietrich molecularresponsetocombinedmolecularandexternalradiotherapyinheadandnecksquamouscellcarcinomahnscc |
| _version_ |
1718412764703096832 |